Camp4 Therapeutics Corp CAMP

Morningstar Rating
$3.77 +0.07 (1.89%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CAMP is trading at a LOCK|jZYkk premium.
Price
$3.76
Fair Value
LOCK|lL?w>g$
Uncertainty
LOCK|@q#yZs
1-Star Price
LOCK|.c<m>T>
5-Star Price
LOCK|x%VG<%
Economic Moat
LOCK|&$
Capital Allocation
—

Trading Information

Previous Close Price
$3.70
Day Range
$3.62–3.87
52-Week Range
$2.86–7.75
Bid/Ask
$3.51 / $3.90
Shares Outstanding
62.75M
Market Cap
$236.58M
Volume/Avg
72,146 / 274,827

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
44.05
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
48

Valuation

Metric
CAMP
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
44.05
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
CAMP
Quick Ratio
4.52
Current Ratio
4.70
Interest Coverage
—
Quick Ratio
CAMP

Profitability

Metric
CAMP
Return on Assets (Normalized)
−48.61%
Return on Equity (Normalized)
−125.09%
Return on Invested Capital (Normalized)
−119.65%
Return on Assets
CAMP

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|s^^DY#JLOCK|sWsB@$129B
Moderna Inc
MRNA
LOCK|>>d>&!LLOCK|^D$$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|<Xm>@hLOCK|QmFSh$77B
argenx SE ADR
ARGX
LOCK|qfVtDJLOCK|SD$$51B
BeOne Medicines Ltd ADR
ONC
LOCK|>QH$V%LOCK|%@$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|D@#w!%ZLOCK|JHP&$31B
Royalty Pharma PLC Class A
RPRX
LOCK|>MZhT&hmLOCK|$?G@$25B
BioNTech SE ADR
BNTX
LOCK|xj^&hPbLOCK|C<?$24B
Incyte Corp
INCY
LOCK|>>Z$S@LOCK|c&$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|$mmb^#LOCK|ZV$14B

Sponsor Center